ImmuCell (NASDAQ:ICCC) Stock Price Crosses Above Two Hundred Day Moving Average - Time to Sell?

Key Points

• ImmuCell shares crossed above their 200-day moving average, reaching $10.49 before closing at $10.06; the stock’s 200-day average is $8.64, compared with a 50-day average of $10.53.
• Analyst sentiment improved, with Weiss Ratings upgrading the stock to “hold” and Wall Street Zen assigning a “strong-buy” rating, though MarketBeat’s overall analyst rating remains “Hold.”
• The company exceeded quarterly expectations, reporting $0.20 in earnings per share versus a $0.05 consensus estimate and $7.19 million in revenue versus $5.40 million expected; its CEO also purchased 8,000 shares.

ImmuCell Corporation (NASDAQ:ICCC - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $8.64 and traded as high as $10.49. ImmuCell shares last traded at $10.06, with a volume of 11,130 shares traded.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Weiss Ratings raised shares of ImmuCell from a "sell (d-)" rating to a "hold (c-)" rating in a research report on Tuesday. Wall Street Zen raised ImmuCell to a "strong-buy" rating in a research report on Saturday, June 27th. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the stock currently has an average rating of "Hold".

ImmuCell Stock Down 0.3%

The business's fifty day moving average price is $10.53 and its 200 day moving average price is $8.64. The company has a market capitalization of $91.34 million, a P/E ratio of 125.77 and a beta of 0.54. The company has a current ratio of 4.75, a quick ratio of 2.71 and a debt-to-equity ratio of 0.22.

ImmuCell (NASDAQ:ICCC - Get Free Report) last posted its earnings results on Thursday, August 13th. The biotechnology company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.05 by $0.15. ImmuCell had a net margin of 2.57% and a return on equity of 2.69%. The business had revenue of $7.19 million for the quarter, compared to analysts' expectations of $5.40 million.

Insiders Place Their Bets

In related news, CEO Boekhorst Paul Francis Oliv Te acquired 8,000 shares of the stock in a transaction dated Thursday, June 18th. The shares were bought at an average cost of $9.49 per share, for a total transaction of $75,920.00. Following the purchase, the chief executive officer owned 17,785 shares in the company, valued at approximately $168,779.65. This trade represents a 81.76% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 5.70% of the company's stock.

Hedge Funds Weigh In On ImmuCell

Hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC boosted its stake in ImmuCell by 4.2% in the 2nd quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company's stock valued at $500,000 after buying an additional 2,907 shares in the last quarter. Mesirow Financial Investment Management Inc. raised its stake in ImmuCell by 199.6% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company's stock worth $224,000 after acquiring an additional 24,303 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in ImmuCell by 3.2% during the first quarter. Dimensional Fund Advisors LP now owns 56,030 shares of the biotechnology company's stock worth $355,000 after acquiring an additional 1,749 shares in the last quarter. Finally, Militia Capital Management LLC acquired a new position in ImmuCell during the first quarter worth $114,000. Institutional investors own 13.47% of the company's stock.

ImmuCell Company Profile

ImmuCell Corporation NASDAQ: ICCC is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company's flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source